Jordyn Sava

In the phase 3 CheckMate-77T trial, a neoadjuvant and adjuvant treatment strategy including nivolumab and chemotherapy improved survival in resectable stage IIA to IIIB non–small cell lung cancer.

For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.

The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.

NXC-201, a next-generation chimeric antigen receptor T-cell therapy, has potential to expand as treatment for patients with amyloid light chain amyloidosis.

Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.

Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.

A supplemental biologics license application seeking the approval of pembrolizumab, external beam radiotherapy, and concurrent chemotherapy, followed by brachytherapy has been accepted for priority review by the FDA for advanced cervical cancer.

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, discusses the impact of trastuzumab deruxtecan, new developments, and unmet needs in the HER2-positive breast cancer space.

A phase 1 trial will evaluate OSM-0205 in healthy subjects with chemotherapy-induced peripheral neuropathy, followed by a phase 2 study in patients with breast cancer.

With a minimum of 73.5 months of follow-up, nivolumab plus ipilimumab showed a benefit in overall survival in patients with treatment-naive stage IV or recurrent non–small cell lung cancer with no known EGFR/ALK alterations.

Atezolizumab, carboplatin, and pemetrexed demonstrated efficacy and safety in patients with advanced lung cancer with untreated brain metastases.

HEMO-CAR-T is an autologous chimeric antigen receptor T-cell therapy being developed against an acute myeloid leukemia target.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, highlighted some of the most recent updates in the field of multiple myeloma, and discussed emerging therapies that show promise.

No adverse events were associated with 64Cu-SAR-Bombesin treatment in patients with prostate cancer, according to findings from the phase 2 BOP trial.

Nadofaragene firadenovec-vncg received FDA approval for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer in 2022, and is now being evaluated further in the ABLE-41 trial.

Data from the phase 2 FIREFLY-1 trial support the new drug application for tovorafenib in relapsed or progressive pediatric low-grade glioma. The regulatory agency anticipates filing the application by mid-November 2023

In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment of patients with LBCL.

The combination of AFM13 with AlloNK has been granted FDA fast track designation and is being investigated in the phase 2 LuminICE-203 study for patients with Hodgkin lymphoma.

In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.

During a webcast, experts discussed the current and future treatment landscape of hepatocellular carcinoma and the need to explore combinations with chemotherapy.

Preclinical data of soquelitinib has demonstrated tumor responses in difficult to treat T-cell malignancies. The agent will now be evaluated in a phase 3 study in relapsed peripheral T cell lymphoma.

Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.

According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.

According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.

In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.

Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.